Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...
Հիմնական հեղինակներ: | Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
Oxford University Press
2016
|
Նմանատիպ նյութեր
-
Evolving concepts in phases I and II drug development for Crohn's Disease
: Jairath, V, և այլն
Հրապարակվել է: (2016) -
The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
: Sandborn, W, և այլն
Հրապարակվել է: (2016) -
Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
: Jairath, V, և այլն
Հրապարակվել է: (2016) -
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
: D'Haens, G, և այլն
Հրապարակվել է: (2009) -
Biosimilars in IBD: hope or expectation?
: Gecse, K, և այլն
Հրապարակվել է: (2013)